nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—GLUL—liver cancer	0.813	0.908	CbGaD
Ceftriaxone—ALB—liver cancer	0.0828	0.0924	CbGaD
Ceftriaxone—Glossodynia—Sorafenib—liver cancer	0.00375	0.0459	CcSEcCtD
Ceftriaxone—Lymphopenia—Sorafenib—liver cancer	0.00245	0.03	CcSEcCtD
Ceftriaxone—Secondary infection—Epirubicin—liver cancer	0.00158	0.0193	CcSEcCtD
Ceftriaxone—Secondary infection—Doxorubicin—liver cancer	0.00146	0.0178	CcSEcCtD
Ceftriaxone—Warmth—Epirubicin—liver cancer	0.00146	0.0178	CcSEcCtD
Ceftriaxone—Proteinuria—Sorafenib—liver cancer	0.00143	0.0175	CcSEcCtD
Ceftriaxone—Protein urine present—Sorafenib—liver cancer	0.00141	0.0172	CcSEcCtD
Ceftriaxone—Glossitis—Sorafenib—liver cancer	0.00136	0.0166	CcSEcCtD
Ceftriaxone—Drug interaction—Sorafenib—liver cancer	0.00135	0.0165	CcSEcCtD
Ceftriaxone—Warmth—Doxorubicin—liver cancer	0.00135	0.0165	CcSEcCtD
Ceftriaxone—Hepatic function abnormal—Sorafenib—liver cancer	0.00104	0.0127	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Sorafenib—liver cancer	0.000964	0.0118	CcSEcCtD
Ceftriaxone—Lactic dehydrogenase activity increased—Epirubicin—liver cancer	0.000905	0.0111	CcSEcCtD
Ceftriaxone—Lymphopenia—Epirubicin—liver cancer	0.000905	0.0111	CcSEcCtD
Ceftriaxone—Lymphopenia—Doxorubicin—liver cancer	0.000837	0.0102	CcSEcCtD
Ceftriaxone—Lactic dehydrogenase activity increased—Doxorubicin—liver cancer	0.000837	0.0102	CcSEcCtD
Ceftriaxone—Local reaction—Epirubicin—liver cancer	0.000836	0.0102	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Sorafenib—liver cancer	0.000831	0.0102	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.000819	0.01	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000819	0.01	CcSEcCtD
Ceftriaxone—Blood lactate dehydrogenase increased—Epirubicin—liver cancer	0.000797	0.00975	CcSEcCtD
Ceftriaxone—Local reaction—Doxorubicin—liver cancer	0.000774	0.00947	CcSEcCtD
Ceftriaxone—Pancreatitis—Sorafenib—liver cancer	0.000771	0.00943	CcSEcCtD
Ceftriaxone—Serum creatinine increased—Epirubicin—liver cancer	0.000753	0.00921	CcSEcCtD
Ceftriaxone—Thrombocytosis—Epirubicin—liver cancer	0.000745	0.00911	CcSEcCtD
Ceftriaxone—Blood lactate dehydrogenase increased—Doxorubicin—liver cancer	0.000737	0.00902	CcSEcCtD
Ceftriaxone—Neutropenia—Sorafenib—liver cancer	0.000735	0.009	CcSEcCtD
Ceftriaxone—Serum creatinine increased—Doxorubicin—liver cancer	0.000696	0.00852	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.000695	0.0085	CcSEcCtD
Ceftriaxone—Thrombocytosis—Doxorubicin—liver cancer	0.000689	0.00843	CcSEcCtD
Ceftriaxone—Renal failure—Sorafenib—liver cancer	0.000689	0.00843	CcSEcCtD
Ceftriaxone—Stomatitis—Sorafenib—liver cancer	0.000683	0.00836	CcSEcCtD
Ceftriaxone—Jaundice—Sorafenib—liver cancer	0.000683	0.00836	CcSEcCtD
Ceftriaxone—Epistaxis—Sorafenib—liver cancer	0.000661	0.00809	CcSEcCtD
Ceftriaxone—Haemoglobin—Sorafenib—liver cancer	0.000632	0.00774	CcSEcCtD
Ceftriaxone—Haemorrhage—Sorafenib—liver cancer	0.000629	0.0077	CcSEcCtD
Ceftriaxone—Dermatitis atopic—Epirubicin—liver cancer	0.000626	0.00766	CcSEcCtD
Ceftriaxone—Fungal infection—Epirubicin—liver cancer	0.0006	0.00734	CcSEcCtD
Ceftriaxone—Erythema multiforme—Sorafenib—liver cancer	0.000595	0.00728	CcSEcCtD
Ceftriaxone—Feeling hot—Epirubicin—liver cancer	0.00059	0.00722	CcSEcCtD
Ceftriaxone—Flushing—Sorafenib—liver cancer	0.000584	0.00715	CcSEcCtD
Ceftriaxone—Dermatitis atopic—Doxorubicin—liver cancer	0.000579	0.00708	CcSEcCtD
Ceftriaxone—Glycosuria—Epirubicin—liver cancer	0.000572	0.00699	CcSEcCtD
Ceftriaxone—Fungal infection—Doxorubicin—liver cancer	0.000555	0.00679	CcSEcCtD
Ceftriaxone—Feeling hot—Doxorubicin—liver cancer	0.000546	0.00668	CcSEcCtD
Ceftriaxone—Dysgeusia—Sorafenib—liver cancer	0.000536	0.00656	CcSEcCtD
Ceftriaxone—Glycosuria—Doxorubicin—liver cancer	0.000529	0.00647	CcSEcCtD
Ceftriaxone—Anaemia—Sorafenib—liver cancer	0.000506	0.0062	CcSEcCtD
Ceftriaxone—Oliguria—Epirubicin—liver cancer	0.000502	0.00615	CcSEcCtD
Ceftriaxone—Glossitis—Epirubicin—liver cancer	0.000502	0.00615	CcSEcCtD
Ceftriaxone—Leukopenia—Sorafenib—liver cancer	0.00049	0.006	CcSEcCtD
Ceftriaxone—Glossitis—Doxorubicin—liver cancer	0.000465	0.00569	CcSEcCtD
Ceftriaxone—Oliguria—Doxorubicin—liver cancer	0.000465	0.00569	CcSEcCtD
Ceftriaxone—Vaginal inflammation—Epirubicin—liver cancer	0.000463	0.00567	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Sorafenib—liver cancer	0.000447	0.00547	CcSEcCtD
Ceftriaxone—Colitis—Epirubicin—liver cancer	0.000445	0.00544	CcSEcCtD
Ceftriaxone—Infection—Sorafenib—liver cancer	0.000444	0.00543	CcSEcCtD
Ceftriaxone—Candida infection—Epirubicin—liver cancer	0.000442	0.00541	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Sorafenib—liver cancer	0.000438	0.00536	CcSEcCtD
Ceftriaxone—Vaginal infection—Epirubicin—liver cancer	0.000437	0.00535	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Epirubicin—liver cancer	0.000435	0.00532	CcSEcCtD
Ceftriaxone—Vaginal inflammation—Doxorubicin—liver cancer	0.000428	0.00524	CcSEcCtD
Ceftriaxone—Colitis—Doxorubicin—liver cancer	0.000411	0.00503	CcSEcCtD
Ceftriaxone—Candida infection—Doxorubicin—liver cancer	0.000409	0.00501	CcSEcCtD
Ceftriaxone—Hypertonia—Epirubicin—liver cancer	0.000406	0.00497	CcSEcCtD
Ceftriaxone—Vaginal infection—Doxorubicin—liver cancer	0.000404	0.00495	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Doxorubicin—liver cancer	0.000402	0.00492	CcSEcCtD
Ceftriaxone—Dyspepsia—Sorafenib—liver cancer	0.000393	0.00482	CcSEcCtD
Ceftriaxone—Phlebitis—Epirubicin—liver cancer	0.00039	0.00477	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Epirubicin—liver cancer	0.000388	0.00475	CcSEcCtD
Ceftriaxone—Hepatic function abnormal—Epirubicin—liver cancer	0.000385	0.00471	CcSEcCtD
Ceftriaxone—Pain—Sorafenib—liver cancer	0.000382	0.00468	CcSEcCtD
Ceftriaxone—Hypertonia—Doxorubicin—liver cancer	0.000376	0.0046	CcSEcCtD
Ceftriaxone—Cefotetan—ALB—liver cancer	0.000373	0.267	CrCbGaD
Ceftriaxone—Gastrointestinal pain—Sorafenib—liver cancer	0.000366	0.00447	CcSEcCtD
Ceftriaxone—Phlebitis—Doxorubicin—liver cancer	0.000361	0.00442	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Doxorubicin—liver cancer	0.000359	0.0044	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Epirubicin—liver cancer	0.000356	0.00436	CcSEcCtD
Ceftriaxone—Hepatic function abnormal—Doxorubicin—liver cancer	0.000356	0.00436	CcSEcCtD
Ceftriaxone—Urticaria—Sorafenib—liver cancer	0.000355	0.00435	CcSEcCtD
Ceftriaxone—Abdominal pain—Sorafenib—liver cancer	0.000353	0.00432	CcSEcCtD
Ceftriaxone—Body temperature increased—Sorafenib—liver cancer	0.000353	0.00432	CcSEcCtD
Ceftriaxone—Renal impairment—Epirubicin—liver cancer	0.000353	0.00432	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Epirubicin—liver cancer	0.000347	0.00425	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00033	0.00403	CcSEcCtD
Ceftriaxone—Hypersensitivity—Sorafenib—liver cancer	0.000329	0.00403	CcSEcCtD
Ceftriaxone—Renal impairment—Doxorubicin—liver cancer	0.000327	0.004	CcSEcCtD
Ceftriaxone—Cefpiramide—ALB—liver cancer	0.000324	0.232	CrCbGaD
Ceftriaxone—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000321	0.00393	CcSEcCtD
Ceftriaxone—Pruritus—Sorafenib—liver cancer	0.000316	0.00387	CcSEcCtD
Ceftriaxone—Ataxia—Epirubicin—liver cancer	0.000316	0.00387	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Epirubicin—liver cancer	0.000315	0.00385	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Epirubicin—liver cancer	0.000307	0.00376	CcSEcCtD
Ceftriaxone—Diarrhoea—Sorafenib—liver cancer	0.000306	0.00374	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000303	0.0037	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000303	0.0037	CcSEcCtD
Ceftriaxone—Dizziness—Sorafenib—liver cancer	0.000296	0.00362	CcSEcCtD
Ceftriaxone—Ataxia—Doxorubicin—liver cancer	0.000292	0.00358	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Doxorubicin—liver cancer	0.000291	0.00357	CcSEcCtD
Ceftriaxone—Eosinophilia—Epirubicin—liver cancer	0.000288	0.00352	CcSEcCtD
Ceftriaxone—Pancreatitis—Epirubicin—liver cancer	0.000285	0.00349	CcSEcCtD
Ceftriaxone—Vomiting—Sorafenib—liver cancer	0.000284	0.00348	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Doxorubicin—liver cancer	0.000284	0.00348	CcSEcCtD
Ceftriaxone—Cefonicid—ALB—liver cancer	0.000283	0.202	CrCbGaD
Ceftriaxone—Rash—Sorafenib—liver cancer	0.000282	0.00345	CcSEcCtD
Ceftriaxone—Dermatitis—Sorafenib—liver cancer	0.000282	0.00345	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00028	0.00343	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00028	0.00343	CcSEcCtD
Ceftriaxone—Headache—Sorafenib—liver cancer	0.00028	0.00343	CcSEcCtD
Ceftriaxone—Neutropenia—Epirubicin—liver cancer	0.000272	0.00332	CcSEcCtD
Ceftriaxone—Eosinophilia—Doxorubicin—liver cancer	0.000266	0.00326	CcSEcCtD
Ceftriaxone—Nausea—Sorafenib—liver cancer	0.000266	0.00325	CcSEcCtD
Ceftriaxone—Pancreatitis—Doxorubicin—liver cancer	0.000264	0.00323	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000257	0.00314	CcSEcCtD
Ceftriaxone—Renal failure—Epirubicin—liver cancer	0.000255	0.00312	CcSEcCtD
Ceftriaxone—Jaundice—Epirubicin—liver cancer	0.000252	0.00309	CcSEcCtD
Ceftriaxone—Stomatitis—Epirubicin—liver cancer	0.000252	0.00309	CcSEcCtD
Ceftriaxone—Neutropenia—Doxorubicin—liver cancer	0.000251	0.00308	CcSEcCtD
Ceftriaxone—Haematuria—Epirubicin—liver cancer	0.000247	0.00302	CcSEcCtD
Ceftriaxone—Epistaxis—Epirubicin—liver cancer	0.000244	0.00299	CcSEcCtD
Ceftriaxone—Agranulocytosis—Epirubicin—liver cancer	0.000242	0.00296	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000238	0.00291	CcSEcCtD
Ceftriaxone—Renal failure—Doxorubicin—liver cancer	0.000236	0.00288	CcSEcCtD
Ceftriaxone—Haemoglobin—Epirubicin—liver cancer	0.000234	0.00286	CcSEcCtD
Ceftriaxone—Jaundice—Doxorubicin—liver cancer	0.000234	0.00286	CcSEcCtD
Ceftriaxone—Stomatitis—Doxorubicin—liver cancer	0.000234	0.00286	CcSEcCtD
Ceftriaxone—Haemorrhage—Epirubicin—liver cancer	0.000233	0.00285	CcSEcCtD
Ceftriaxone—Haematuria—Doxorubicin—liver cancer	0.000229	0.0028	CcSEcCtD
Ceftriaxone—Epistaxis—Doxorubicin—liver cancer	0.000226	0.00277	CcSEcCtD
Ceftriaxone—Agranulocytosis—Doxorubicin—liver cancer	0.000224	0.00274	CcSEcCtD
Ceftriaxone—Erythema multiforme—Epirubicin—liver cancer	0.00022	0.00269	CcSEcCtD
Ceftriaxone—Haemoglobin—Doxorubicin—liver cancer	0.000216	0.00265	CcSEcCtD
Ceftriaxone—Flushing—Epirubicin—liver cancer	0.000216	0.00264	CcSEcCtD
Ceftriaxone—Haemorrhage—Doxorubicin—liver cancer	0.000215	0.00263	CcSEcCtD
Ceftriaxone—Chills—Epirubicin—liver cancer	0.000209	0.00255	CcSEcCtD
Ceftriaxone—Erythema multiforme—Doxorubicin—liver cancer	0.000203	0.00249	CcSEcCtD
Ceftriaxone—Flushing—Doxorubicin—liver cancer	0.0002	0.00244	CcSEcCtD
Ceftriaxone—Flatulence—Epirubicin—liver cancer	0.000199	0.00244	CcSEcCtD
Ceftriaxone—Dysgeusia—Epirubicin—liver cancer	0.000198	0.00243	CcSEcCtD
Ceftriaxone—Chills—Doxorubicin—liver cancer	0.000193	0.00236	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Epirubicin—liver cancer	0.000188	0.0023	CcSEcCtD
Ceftriaxone—Anaemia—Epirubicin—liver cancer	0.000187	0.00229	CcSEcCtD
Ceftriaxone—Agitation—Epirubicin—liver cancer	0.000186	0.00228	CcSEcCtD
Ceftriaxone—Flatulence—Doxorubicin—liver cancer	0.000185	0.00226	CcSEcCtD
Ceftriaxone—Dysgeusia—Doxorubicin—liver cancer	0.000183	0.00224	CcSEcCtD
Ceftriaxone—Malaise—Epirubicin—liver cancer	0.000183	0.00223	CcSEcCtD
Ceftriaxone—Leukopenia—Epirubicin—liver cancer	0.000181	0.00222	CcSEcCtD
Ceftriaxone—Palpitations—Epirubicin—liver cancer	0.000179	0.00219	CcSEcCtD
Ceftriaxone—Convulsion—Epirubicin—liver cancer	0.000175	0.00215	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Doxorubicin—liver cancer	0.000174	0.00213	CcSEcCtD
Ceftriaxone—Anaemia—Doxorubicin—liver cancer	0.000173	0.00212	CcSEcCtD
Ceftriaxone—Agitation—Doxorubicin—liver cancer	0.000172	0.00211	CcSEcCtD
Ceftriaxone—Discomfort—Epirubicin—liver cancer	0.00017	0.00208	CcSEcCtD
Ceftriaxone—Malaise—Doxorubicin—liver cancer	0.000169	0.00207	CcSEcCtD
Ceftriaxone—Leukopenia—Doxorubicin—liver cancer	0.000168	0.00205	CcSEcCtD
Ceftriaxone—Cefoperazone—ALB—liver cancer	0.000167	0.119	CrCbGaD
Ceftriaxone—Palpitations—Doxorubicin—liver cancer	0.000166	0.00203	CcSEcCtD
Ceftriaxone—Oedema—Epirubicin—liver cancer	0.000165	0.00202	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Epirubicin—liver cancer	0.000165	0.00202	CcSEcCtD
Ceftriaxone—Infection—Epirubicin—liver cancer	0.000164	0.00201	CcSEcCtD
Ceftriaxone—Convulsion—Doxorubicin—liver cancer	0.000162	0.00199	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Epirubicin—liver cancer	0.000162	0.00198	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Epirubicin—liver cancer	0.00016	0.00195	CcSEcCtD
Ceftriaxone—Discomfort—Doxorubicin—liver cancer	0.000158	0.00193	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—CASP3—liver cancer	0.000157	0.0076	CbGpPWpGaD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000156	0.00756	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000155	0.0075	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000155	0.0075	CbGpPWpGaD
Ceftriaxone—Anaphylactic shock—Doxorubicin—liver cancer	0.000153	0.00187	CcSEcCtD
Ceftriaxone—Oedema—Doxorubicin—liver cancer	0.000153	0.00187	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—JUN—liver cancer	0.000152	0.00738	CbGpPWpGaD
Ceftriaxone—Infection—Doxorubicin—liver cancer	0.000152	0.00186	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Doxorubicin—liver cancer	0.00015	0.00183	CcSEcCtD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000149	0.00721	CbGpPWpGaD
Ceftriaxone—Paraesthesia—Epirubicin—liver cancer	0.000148	0.00182	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Doxorubicin—liver cancer	0.000148	0.00181	CcSEcCtD
Ceftriaxone—ALB—FOXA2 and FOXA3 transcription factor networks—HNF4A—liver cancer	0.000147	0.00712	CbGpPWpGaD
Ceftriaxone—Dyspepsia—Epirubicin—liver cancer	0.000145	0.00178	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—MAPK8—liver cancer	0.000144	0.00698	CbGpPWpGaD
Ceftriaxone—Pain—Epirubicin—liver cancer	0.000141	0.00173	CcSEcCtD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000139	0.00672	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000138	0.00667	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000138	0.00667	CbGpPWpGaD
Ceftriaxone—Paraesthesia—Doxorubicin—liver cancer	0.000137	0.00168	CcSEcCtD
Ceftriaxone—Cefazolin—ALB—liver cancer	0.000137	0.098	CrCbGaD
Ceftriaxone—Feeling abnormal—Epirubicin—liver cancer	0.000136	0.00167	CcSEcCtD
Ceftriaxone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A1—liver cancer	0.000135	0.00656	CbGpPWpGaD
Ceftriaxone—Gastrointestinal pain—Epirubicin—liver cancer	0.000135	0.00165	CcSEcCtD
Ceftriaxone—Dyspepsia—Doxorubicin—liver cancer	0.000135	0.00165	CcSEcCtD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000132	0.00641	CbGpPWpGaD
Ceftriaxone—Urticaria—Epirubicin—liver cancer	0.000131	0.00161	CcSEcCtD
Ceftriaxone—Pain—Doxorubicin—liver cancer	0.000131	0.0016	CcSEcCtD
Ceftriaxone—Body temperature increased—Epirubicin—liver cancer	0.000131	0.0016	CcSEcCtD
Ceftriaxone—Abdominal pain—Epirubicin—liver cancer	0.000131	0.0016	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—UGDH—liver cancer	0.000129	0.00624	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Doxorubicin—liver cancer	0.000126	0.00154	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000125	0.00153	CcSEcCtD
Ceftriaxone—Hypersensitivity—Epirubicin—liver cancer	0.000122	0.00149	CcSEcCtD
Ceftriaxone—Urticaria—Doxorubicin—liver cancer	0.000121	0.00149	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—EPT1—liver cancer	0.000121	0.00587	CbGpPWpGaD
Ceftriaxone—Body temperature increased—Doxorubicin—liver cancer	0.000121	0.00148	CcSEcCtD
Ceftriaxone—Abdominal pain—Doxorubicin—liver cancer	0.000121	0.00148	CcSEcCtD
Ceftriaxone—Pruritus—Epirubicin—liver cancer	0.000117	0.00143	CcSEcCtD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000116	0.00561	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000115	0.00557	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000115	0.00557	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—TAT—liver cancer	0.000115	0.00556	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—TNF—liver cancer	0.000114	0.00552	CbGpPWpGaD
Ceftriaxone—Cefalotin—ALB—liver cancer	0.000114	0.0813	CrCbGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—KRAS—liver cancer	0.000113	0.00548	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Epirubicin—liver cancer	0.000113	0.00138	CcSEcCtD
Ceftriaxone—Hypersensitivity—Doxorubicin—liver cancer	0.000113	0.00138	CcSEcCtD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—BRAF—liver cancer	0.000112	0.00544	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—GPX3—liver cancer	0.000111	0.00537	CbGpPWpGaD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000111	0.00535	CbGpPWpGaD
Ceftriaxone—Dizziness—Epirubicin—liver cancer	0.000109	0.00134	CcSEcCtD
Ceftriaxone—Pruritus—Doxorubicin—liver cancer	0.000108	0.00132	CcSEcCtD
Ceftriaxone—Vomiting—Epirubicin—liver cancer	0.000105	0.00129	CcSEcCtD
Ceftriaxone—Diarrhoea—Doxorubicin—liver cancer	0.000105	0.00128	CcSEcCtD
Ceftriaxone—Rash—Epirubicin—liver cancer	0.000104	0.00127	CcSEcCtD
Ceftriaxone—Dermatitis—Epirubicin—liver cancer	0.000104	0.00127	CcSEcCtD
Ceftriaxone—Headache—Epirubicin—liver cancer	0.000103	0.00127	CcSEcCtD
Ceftriaxone—Dizziness—Doxorubicin—liver cancer	0.000101	0.00124	CcSEcCtD
Ceftriaxone—Nausea—Epirubicin—liver cancer	9.81e-05	0.0012	CcSEcCtD
Ceftriaxone—Vomiting—Doxorubicin—liver cancer	9.72e-05	0.00119	CcSEcCtD
Ceftriaxone—Rash—Doxorubicin—liver cancer	9.64e-05	0.00118	CcSEcCtD
Ceftriaxone—Dermatitis—Doxorubicin—liver cancer	9.63e-05	0.00118	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—HRAS—liver cancer	9.62e-05	0.00466	CbGpPWpGaD
Ceftriaxone—Headache—Doxorubicin—liver cancer	9.58e-05	0.00117	CcSEcCtD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—RAF1—liver cancer	9.39e-05	0.00454	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—SERPINA1—liver cancer	9.37e-05	0.00454	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—SLC11A2—liver cancer	9.25e-05	0.00448	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—IL6—liver cancer	9.21e-05	0.00446	CbGpPWpGaD
Ceftriaxone—Nausea—Doxorubicin—liver cancer	9.08e-05	0.00111	CcSEcCtD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—SERPINA1—liver cancer	8.93e-05	0.00432	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—SLC40A1—liver cancer	8.83e-05	0.00427	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—GPX3—liver cancer	8.81e-05	0.00427	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—BRAF—liver cancer	8.61e-05	0.00417	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—SLC11A2—liver cancer	8.55e-05	0.00414	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—AKT1—liver cancer	8.49e-05	0.00411	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ATP7B—liver cancer	8.46e-05	0.0041	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ANXA2—liver cancer	8.46e-05	0.0041	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—SLC40A1—liver cancer	8.16e-05	0.00395	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—NR1H4—liver cancer	8e-05	0.00388	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC11A2—liver cancer	7.93e-05	0.00384	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ANXA2—liver cancer	7.82e-05	0.00379	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ATP7B—liver cancer	7.82e-05	0.00379	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CPT1B—liver cancer	7.81e-05	0.00378	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC40A1—liver cancer	7.57e-05	0.00367	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—NR1H4—liver cancer	7.53e-05	0.00364	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTA3—liver cancer	7.4e-05	0.00358	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—NR1H4—liver cancer	7.39e-05	0.00358	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ATP7B—liver cancer	7.26e-05	0.00351	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ANXA2—liver cancer	7.26e-05	0.00351	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—RAF1—liver cancer	7.19e-05	0.00348	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC11A2—liver cancer	7.06e-05	0.00342	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—MTHFR—liver cancer	7e-05	0.00339	CbGpPWpGaD
Ceftriaxone—ALB—FOXA2 and FOXA3 transcription factor networks—F2—liver cancer	6.91e-05	0.00335	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—NR1H4—liver cancer	6.86e-05	0.00332	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTA4—liver cancer	6.77e-05	0.00328	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC40A1—liver cancer	6.73e-05	0.00326	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTA2—liver cancer	6.6e-05	0.00319	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ANXA2—liver cancer	6.45e-05	0.00313	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ATP7B—liver cancer	6.45e-05	0.00313	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTA1—liver cancer	6.36e-05	0.00308	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—NAT2—liver cancer	6.29e-05	0.00305	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—GGT1—liver cancer	6.2e-05	0.003	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—F2—liver cancer	6.14e-05	0.00297	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—NR1H4—liver cancer	6.1e-05	0.00296	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ALDOB—liver cancer	6.03e-05	0.00292	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC11A2—liver cancer	6.03e-05	0.00292	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC9C1—liver cancer	5.98e-05	0.0029	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—MYO5B—liver cancer	5.98e-05	0.0029	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC11A2—liver cancer	5.89e-05	0.00285	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—IGF2—liver cancer	5.85e-05	0.00283	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CRABP1—liver cancer	5.76e-05	0.00279	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC40A1—liver cancer	5.75e-05	0.00278	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—MTHFR—liver cancer	5.69e-05	0.00276	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC40A1—liver cancer	5.62e-05	0.00272	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—liver cancer	5.57e-05	0.0027	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—HGF—liver cancer	5.52e-05	0.00267	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ATP7B—liver cancer	5.39e-05	0.00261	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ANXA2—liver cancer	5.39e-05	0.00261	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—HGF—liver cancer	5.26e-05	0.00255	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HBE1—liver cancer	5.24e-05	0.00254	CbGpPWpGaD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—HRAS—liver cancer	5.17e-05	0.0025	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—SERPINE1—liver cancer	5.11e-05	0.00248	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—NR1H4—liver cancer	5.09e-05	0.00247	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—HPGDS—liver cancer	5.03e-05	0.00244	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—F2—liver cancer	5e-05	0.00242	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—MTHFR—liver cancer	4.52e-05	0.00219	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PSMD10—liver cancer	4.48e-05	0.00217	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PSMA4—liver cancer	4.48e-05	0.00217	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—EPT1—liver cancer	4.48e-05	0.00217	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GOT2—liver cancer	4.36e-05	0.00211	CbGpPWpGaD
Ceftriaxone—SLC22A11—SLC-mediated transmembrane transport—ALB—liver cancer	4.19e-05	0.00203	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—SERPINE1—liver cancer	4.16e-05	0.00201	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SERPINA1—liver cancer	4.16e-05	0.00201	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CYP2E1—liver cancer	4.1e-05	0.00199	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—CYCS—liver cancer	4.08e-05	0.00198	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—F2—liver cancer	3.97e-05	0.00192	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—HRAS—liver cancer	3.96e-05	0.00192	CbGpPWpGaD
Ceftriaxone—SLC15A2—SLC-mediated transmembrane transport—ALB—liver cancer	3.87e-05	0.00187	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CYCS—liver cancer	3.84e-05	0.00186	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—CYCS—liver cancer	3.77e-05	0.00182	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GOT1—liver cancer	3.76e-05	0.00182	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GGT1—liver cancer	3.76e-05	0.00182	CbGpPWpGaD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—ALB—liver cancer	3.59e-05	0.00174	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—SERPINE1—liver cancer	3.57e-05	0.00173	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—HMOX1—liver cancer	3.55e-05	0.00172	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—CYCS—liver cancer	3.5e-05	0.00169	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—liver cancer	3.4e-05	0.00164	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTP1—liver cancer	3.38e-05	0.00164	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—IL2—liver cancer	3.37e-05	0.00163	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—HMOX1—liver cancer	3.34e-05	0.00161	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—SERPINE1—liver cancer	3.3e-05	0.0016	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—HMOX1—liver cancer	3.28e-05	0.00159	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ANXA2—liver cancer	3.23e-05	0.00157	CbGpPWpGaD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—ALB—liver cancer	3.2e-05	0.00155	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—CYCS—liver cancer	3.11e-05	0.00151	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTM1—liver cancer	3.11e-05	0.0015	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC11A2—liver cancer	3.06e-05	0.00148	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—HMOX1—liver cancer	3.04e-05	0.00147	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—TNF—liver cancer	3.01e-05	0.00146	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CYP1A1—liver cancer	2.95e-05	0.00143	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC40A1—liver cancer	2.92e-05	0.00141	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	2.89e-05	0.0014	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—PPARA—liver cancer	2.86e-05	0.00139	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ATP7B—liver cancer	2.8e-05	0.00136	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ANXA2—liver cancer	2.8e-05	0.00136	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	2.78e-05	0.00135	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—MTHFR—liver cancer	2.75e-05	0.00133	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PRKCE—liver cancer	2.74e-05	0.00133	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—HMOX1—liver cancer	2.7e-05	0.00131	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PPARA—liver cancer	2.69e-05	0.0013	CbGpPWpGaD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—ALB—liver cancer	2.67e-05	0.00129	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—NR1H4—liver cancer	2.65e-05	0.00128	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—PPARA—liver cancer	2.65e-05	0.00128	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—CYCS—liver cancer	2.6e-05	0.00126	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IGF2—liver cancer	2.59e-05	0.00126	CbGpPWpGaD
Ceftriaxone—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—liver cancer	2.52e-05	0.00122	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—PPARA—liver cancer	2.46e-05	0.00119	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—VEGFA—liver cancer	2.45e-05	0.00119	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—TNF—liver cancer	2.45e-05	0.00119	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—HGF—liver cancer	2.45e-05	0.00119	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—IL6—liver cancer	2.43e-05	0.00118	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—CSF2—liver cancer	2.42e-05	0.00117	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—liver cancer	2.34e-05	0.00113	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CG—liver cancer	2.31e-05	0.00112	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—HMOX1—liver cancer	2.26e-05	0.00109	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—TGFB1—liver cancer	2.25e-05	0.00109	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PPARG—liver cancer	2.23e-05	0.00108	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—PPARA—liver cancer	2.18e-05	0.00106	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—TP53—liver cancer	2.16e-05	0.00105	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—liver cancer	2.14e-05	0.00104	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SERPINA1—liver cancer	2.14e-05	0.00104	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ALB—liver cancer	2.13e-05	0.00103	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	2.13e-05	0.00103	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—UGDH—liver cancer	2.12e-05	0.00103	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CD—liver cancer	2.03e-05	0.000982	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ALB—liver cancer	2e-05	0.00097	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—EPT1—liver cancer	2e-05	0.000966	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—IL6—liver cancer	1.98e-05	0.000958	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ALB—liver cancer	1.97e-05	0.000953	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—MAPK14—liver cancer	1.96e-05	0.00095	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—TNF—liver cancer	1.95e-05	0.000943	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—RAF1—liver cancer	1.93e-05	0.000932	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—F2—liver cancer	1.9e-05	0.00092	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TAT—liver cancer	1.89e-05	0.000916	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	1.86e-05	0.000901	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ALB—liver cancer	1.83e-05	0.000884	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—PPARA—liver cancer	1.82e-05	0.000883	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	1.82e-05	0.000881	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—RAF1—liver cancer	1.78e-05	0.000861	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CB—liver cancer	1.77e-05	0.000856	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—RAF1—liver cancer	1.65e-05	0.000799	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ALB—liver cancer	1.62e-05	0.000786	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	1.6e-05	0.000774	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IFNA1—liver cancer	1.6e-05	0.000773	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	1.58e-05	0.000766	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—IL6—liver cancer	1.57e-05	0.000761	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—RAF1—liver cancer	1.47e-05	0.000711	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	1.43e-05	0.000691	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PRKCE—liver cancer	1.41e-05	0.000683	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	1.39e-05	0.000675	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.39e-05	0.000674	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ALB—liver cancer	1.36e-05	0.000656	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	1.35e-05	0.000654	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ABL1—liver cancer	1.34e-05	0.00065	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IGF2—liver cancer	1.34e-05	0.000648	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CPT1B—liver cancer	1.29e-05	0.000623	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GLUL—liver cancer	1.29e-05	0.000623	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	1.28e-05	0.00062	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HGF—liver cancer	1.26e-05	0.000611	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CSF2—liver cancer	1.25e-05	0.000605	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NR1H4—liver cancer	1.24e-05	0.000601	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—RAF1—liver cancer	1.23e-05	0.000593	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA3—liver cancer	1.22e-05	0.00059	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	1.17e-05	0.000568	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA4—liver cancer	1.12e-05	0.00054	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.09e-05	0.000528	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	1.09e-05	0.000527	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA2—liver cancer	1.09e-05	0.000526	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CA—liver cancer	1.08e-05	0.000522	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTA1—liver cancer	1.05e-05	0.000508	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NAT2—liver cancer	1.04e-05	0.000502	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—MAPK14—liver cancer	1.01e-05	0.00049	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	9.99e-06	0.000484	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	9.97e-06	0.000483	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ALDOB—liver cancer	9.94e-06	0.000481	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—F2—liver cancer	9.8e-06	0.000474	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CRABP1—liver cancer	9.48e-06	0.000459	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	9.48e-06	0.000459	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CG—liver cancer	9.38e-06	0.000454	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—AKT1—liver cancer	8.81e-06	0.000426	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	8.54e-06	0.000413	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	8.5e-06	0.000411	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HPGDS—liver cancer	8.29e-06	0.000401	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CD—liver cancer	8.24e-06	0.000399	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.24e-06	0.000399	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SERPINE1—liver cancer	8.15e-06	0.000395	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.51e-06	0.000363	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PSMA4—liver cancer	7.39e-06	0.000358	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PSMD10—liver cancer	7.39e-06	0.000358	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—RAF1—liver cancer	7.36e-06	0.000356	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GOT2—liver cancer	7.19e-06	0.000348	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CB—liver cancer	7.19e-06	0.000348	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	6.94e-06	0.000336	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP2E1—liver cancer	6.76e-06	0.000327	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL2—liver cancer	6.6e-06	0.00032	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.54e-06	0.000317	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	6.37e-06	0.000308	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYCS—liver cancer	6.32e-06	0.000306	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GGT1—liver cancer	6.2e-06	0.0003	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GOT1—liver cancer	6.2e-06	0.0003	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—VEGFA—liver cancer	5.61e-06	0.000272	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTP1—liver cancer	5.57e-06	0.00027	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HMOX1—liver cancer	5.5e-06	0.000266	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TGFB1—liver cancer	5.15e-06	0.000249	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTM1—liver cancer	5.12e-06	0.000248	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP1A1—liver cancer	4.85e-06	0.000235	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—KRAS—liver cancer	4.77e-06	0.000231	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MTHFR—liver cancer	4.53e-06	0.000219	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PPARA—liver cancer	4.44e-06	0.000215	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CA—liver cancer	4.38e-06	0.000212	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TP53—liver cancer	4.24e-06	0.000205	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HRAS—liver cancer	4.05e-06	0.000196	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.99e-06	0.000193	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CG—liver cancer	3.8e-06	0.000184	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PPARG—liver cancer	3.67e-06	0.000178	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—AKT1—liver cancer	3.58e-06	0.000173	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CD—liver cancer	3.34e-06	0.000162	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CB—liver cancer	2.91e-06	0.000141	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CA—liver cancer	1.78e-06	8.6e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AKT1—liver cancer	1.45e-06	7.02e-05	CbGpPWpGaD
